Targeting Pyk2 for therapeutic intervention
Authors:
- 9 December 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 14 (1) , 95-108
Abstract
(2010). Targeting Pyk2 for therapeutic intervention. Expert Opinion on Therapeutic Targets: Vol. 14, No. 1, pp. 95-108.Keywords
This publication has 128 references indexed in Scilit:
- Extended survival of Pyk2 or FAK deficient orthotopic glioma xenograftsJournal of Neuro-Oncology, 2008
- Focal adhesion kinase as a regulator of cell tension in the progression of cancerSeminars in Cancer Biology, 2008
- Reaching for high-hanging fruit in drug discovery at protein–protein interfacesNature, 2007
- Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisProceedings of the National Academy of Sciences, 2007
- The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrenceBritish Journal of Cancer, 2007
- Structural Basis for the Autoinhibition of Focal Adhesion KinaseCell, 2007
- The role of focal-adhesion kinase in cancer — a new therapeutic opportunityNature Reviews Cancer, 2005
- Focal adhesion kinase: in command and control of cell motilityNature Reviews Molecular Cell Biology, 2005
- Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibitionNature Structural & Molecular Biology, 2004
- Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient miceNature, 1995